Corporate investment in family-building benefits continues to shatter records. Progyny, a prominent manager of employer-sponsored fertility programs, successfully onboarded an unprecedented 1.3 million new covered lives heading into 2027 during its latest selling cycle. Yet, the federal safety net guaranteeing workers the time off required to utilize these exact medical benefits is facing a drastic contraction.

The Equal Employment Opportunity Commission (EEOC) is actively moving to revise its regulatory guidelines under the Pregnant Workers Fairness Act (PWFA). According to reports from The New York Times, fertility treatments are slated to lose explicit federal protection under this narrowed interpretation. Should this adjustment take effect, taking time off for procedures like in vitro fertilization (IVF) will pivot from a protected legal right into a discretionary workplace perk—benefits that traditionally track employee compensation tiers. This looming shift heightens the exposure for hourly earners, corporate buyers of fertility plans, and the broader women’s health sector.

Corporate Demand For Fertility Benefits Reaches New Highs

As its upcoming accounts activate in 2027, Progyny anticipates servicing upwards of 660 corporate clients alongside roughly 8.3 million covered lives. The enterprise reported an 8.9% uptick in third-quarter revenue, reaching $341.3 million, mirroring a wider market trajectory. Data from Mercer’s annual benefits report indicates that 70% of large U.S. corporations with workforces exceeding 20,000 provided IVF coverage in 2024, alongside 47% of firms with 500 or more employees—a sharp increase from just 22% among large employers in 2019.

Financing medical treatments addresses only a fraction of the challenge, given that IVF cycles operate strictly according to biological timelines rather than corporate calendars. Medical monitoring and surgical interventions frequently demand execution within tight windows of a few days or even hours following physician directives. Cynthia McEwen, Progyny’s GVP of People, Experience & Opportunity, points out that fertility treatments are acutely time-sensitive, leaving patients without the flexibility to align appointments around standard office hours. When employees are blocked from attending, McEwen warns that a single missed visit jeopardizes an entire clinical cycle.

The Real-World Impacts of a Pregnancy Rule Rollback

Congress originally enacted the Pregnant Workers Fairness Act in 2022 via bipartisan backing, mandating reasonable accommodations for limitations linked to pregnancy, childbirth, or related medical conditions, though the statute omitted a precise definition for that final clause. The EEOC filled that regulatory gap in 2024 by publishing an expansive inclusion list encompassing fertility interventions, endometriosis, menstruation, and contraception.

However, EEOC Chair Andrea Lucas dissented from that original framework. In her 2024 statement opposing the guidance, she argued that menstruation, infertility, and menopause are neither caused nor worsened by specific pregnancies or childbirth events. Employment attorneys have monitored these developments closely. Deniz Uzel Reilly, an attorney at the employer-defense law firm Fisher Phillips, noted to Bloomberg Law that Lucas has consistently challenged the applicability of the PWFA to reproductive capacity, which inherently covers fertility care.

While the underlying statute remains unchanged, Gaylynn Burroughs—vice president for education and workplace justice at the National Women’s Law Center—emphasizes that administrative actions cannot overwrite federal law. Employees undergoing IVF maintain the legal basis to argue for coverage, though they would be forced to litigate those claims individually across separate employers and courtrooms.

With newly established legislative majorities holding limited capacity to halt the administrative shift—which operates as a regulation rather than a statutory bill and would survive a presidential veto—the regulatory direction appears set. Furthermore, the White House nomination of Department of Justice official Matt Zandi to the EEOC secures a conservative commission majority as current Democratic terms expire.

IVF Time Off Shifts Toward a Wealth-Dependent Perk

Legal rights universally protect all qualifying workers, whereas perks remain restricted to select personnel whose employers voluntarily provide them, a demographic heavily skewed toward higher earners. Bureau of Labor Statistics data from March 2025 reveals that 96% of top-decile private-sector earners enjoyed paid sick leave, compared to just 41% within the lowest-paid decile.

Without explicit backing from EEOC guidelines, hourly workers requesting schedule adjustments or brief absences for clinical monitoring lose their most definitive federal recourse. While certain individuals may qualify for unpaid leave through the Family and Medical Leave Act—which restricts eligibility strictly to companies with 50-plus workers alongside strict tenure criteria—others face direct financial penalties. McEwen cautions that employees lacking scheduling flexibility may be forced to sacrifice wages or make the impossible choice between retaining their income and pursuing necessary medical care.

Simultaneously, corporate management would inherit complex judgment calls previously standardized by federal rules. Gillian Thomas, senior counsel at the American Civil Liberties Union’s Women’s Rights Project, cautioned in the Times report that the modification positions employers to make direct medical determinations regarding their workers' reproductive health.

Founders in Women’s Health Reject Rollback Advantages

In theory, a restricted rule could drive demand for specific women's health products designed around workday constraints when employees lose official leave options. Yet, industry founders positioned to capture that demand openly reject the premise.

Keira Krausz, CEO of the telehealth platform Wisp, notes that while asynchronous sexual and reproductive care could see increased utilization due to a narrower rule, her company refuses to view diminished workplace protections as a commercial victory. She expresses deep concern that women might retain nominal access to treatments on paper while remaining physically unable to leave their work stations to receive them.

Carolin Archibald, CEO of wearable breast pump manufacturer Willow, identifies a parallel limitation. Although the PUMP Act guarantees break times and private spaces for nursing mothers, a scaled-back EEOC interpretation could relegate other lactation accommodations to managerial discretion. Archibald concedes that product appeal might rise, but maintains that no device can substitute for active employer support, asking a fundamental operational question: if a mother needs to pump during a hectic shift, does she have guaranteed coverage and a designated space?

Investors confront equivalent strategic dilemmas. Alex Taylor, co-founder of Perelel and a prominent women's health advocate, views the policy rollback as a systemic regulatory failure that commercial goods cannot rectify. She advises capital allocators to clearly separate political volatility from fundamental clinical demand.

Corporate Lessons from Progyny’s Internal Policy

Progyny has already resolved this operational question internally for its own personnel. McEwen confirms that company policy maintains accommodation evaluations under the comprehensive definition of related medical conditions, backed by remote and hybrid work structures, flexible scheduling, and supplemental personal leave days.

Any commercial enterprise can adopt this standard regardless of final EEOC publications. For organizations already subsidizing IVF benefits, economic logic supports the move, as an un-schedulable benefit generates zero operational return. Ultimately, McEwen observes, providing financial coverage represents only part of the equation.

Following the expected publication of the EEOC proposal, a public comment window—projected by Ogletree Deakins to extend through January—will offer stakeholders across corporate governance and advocacy a chance to respond. Until a finalized rule takes effect, employee handbooks will serve as the definitive arbiter of who secures time off for fertility treatments.